Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy

References

• Eichhorst B, Robak T, Montserrat E, et al. e-update 2016, refers to Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;26(Suppl5):v78-84
   Web of Science ®Google Scholar
• SEER. SEER. Prevalence database: “US Estimated 37-year L-D prevalence counts on 1/1/2012”. National Cancer Institute, DCCPS, Surveillance Research Program, Data Modeling Branch, released April 2015, based on the November 2014 SEER data submission. 2012. http://surveillance.cancer.gov/prevalence/canques.html. [Last ccessed 8 February 2016]
   Google Scholar
• European Medicines Agency. Medicines for rare diseases. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000034.jsp. [Last accessed August 2016]
   Google Scholar
• Gribben JG. How I treat CLL up front. Blood 2010;115:187-97
   PubMed Web of Science ®Google Scholar
• Mir MA. Chronic lymphocytic leukemia. Medscape Drugs and Diseases [Internet]; 2016. http://emedicine.medscape.com/article/199313-overview
   Google Scholar
• Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002;94:2033-9
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• Holtzer-Goor KM, Schaafsma MR, Joosten P, et al. Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study. Qual Life Res 2015;24:2895-906
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Center Network. Clinical practice guidelines in oncology: Non-Hodgkin’s Lymphomas, v3.2016; 2016. www.nccn.org
   Google Scholar
• Gilead Sciences Ltd. Zydelig (idelalisib): Summary of product characteristics; 2016. https://www.medicines.org.uk/emc/medicine/29201. [Last accessed 14 June 2017]
   Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 376:1164-74
   PubMed Web of Science ®Google Scholar
• Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. ASH Education Program Book 2013;2013:158-67
   Google Scholar
• Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymph 2008;49:49-56
   PubMed Web of Science ®Google Scholar
• Jeyakumaran D, Kempel A, Cote S. An assessment of the number of chronic lymphocytic leukemia (CLL) patients eligible for front-line treatment but unsuitable for full-dose fludarabine across the European Union. Value Health 19:A574-A5
   Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425-37
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23
   PubMed Web of Science ®Google Scholar
• Xu Y, Fahrbach K, Dorman E, et al. A Bayesian network meta-analysis (NMA) of therapies for treatment-naïve chronic lymphocytic leukemia (TN-CLL) patients ineligible for full-dose fludarabine therapy. ISPOR 22nd Annual International Meeting 2017, Boston, MA, USA, May 20-24, 2017
   Google Scholar
• Sorensen S, Wildgust M, Sengupta N, et al. Indirect treatment comparisons of ibrutinib versus physician’s choice and idelalisib plus ofatumumab in patients with previously treated chronic lymphocytic leukemia. Clin Ther 2017;39:178-89e5
   PubMed Web of Science ®Google Scholar
• Österborg A, Udvardy M, Zaritskey A, et al. Ofatumumab (OFA) vs. physician’s choice (PC) of therapy in patients (pts) with bulky fludarabine refractory (BFR) chronic lymphocytic leukaemia (CLL): results of the phase III study OMB114242. Blood 2014;124:4684
   Web of Science ®Google Scholar
• Jones JJ, Wach M, Robak T, et al. Results of a phase 3 randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). ASCO Annual Meeting. Chicago, IL, USA. 29 May-2 June 2015
   Google Scholar
• National Institute for Health and Care Excellence (NICE). TA 343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia; 25 April 2017. http://www.nice.org.uk/guidance/TA343/Evidence
   Google Scholar
• Kosmas CE, Shingler SL, Samanta K, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leuk Lymph 2015;56:1320-6
   PubMed Web of Science ®Google Scholar
• Beusterien KM, Davies J, Leach M, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes 2010;8:50
   PubMed Web of Science ®Google Scholar
• Kay NE, Flowers CR, Weiss M, et al. Variation in health-related quality of life by line of therapy of patients with chronic lymphocytic leukemia. Blood 2015;120:3926
   Google Scholar
• Herring W, Pearson I, Purser M, et al. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Value Health 2014;17:A633
   PubMed Web of Science ®Google Scholar
• Zent CS. Improving quality of life in chronic lymphocytic leukemia. Leuk Lymph 2012;53:1247-8
   PubMed Web of Science ®Google Scholar
• Barr PM, Kipps T, Robak T, et al. Improvement in hematologic function, disease burden/symptoms with ibrutinib in older treatment-naïve (TN) patients with chronic lymphocytic leukemia (CLL) in phase 3 RESONATE-2. Annual Scientific Meeting of the American Geriatrics Society (AGS); Long Beach, FL, USA. May 2016
   Google Scholar
• Garau M, Shah KK, Mason AR, et al. Using QALYs in cancer: a review of the methodological limitations. Pharmacoeconomics 2011;29:673-85
   PubMed Web of Science ®Google Scholar
• Ghia P, Tedeschi A, Barr PM, et al. Improvement in quality of life and well-being in older patients with treatment-naïve (TN) CLL: Results from the randomized phase 3 study of ibrutinib (IBR) versus chlorambucil (CLB) (RESONATE-2). European Haematology Association Annual Meeting, Copenhagen, Denmark, 10 June 2016
   Google Scholar
• Eichhorst B, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-91
   PubMed Web of Science ®Google Scholar
• Hancock SWB, Hyde C. Fludarabine as first line therapy for chronic lymphocytic leukaemia. Report 42. Birmingham, UK: Department of Public Health & Epidemiology, University of Birmingham; 2002
   Google Scholar
• Chen Q, Jain N, Ayer T, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol 2017;35:166-74
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-10
   PubMed Web of Science ®Google Scholar
• Tolley K, Goad C, Yi Y, et al. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ 2013;14:749-59
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Appraisal consultation document: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. NICE; London, UK. 2014
   Google Scholar
• Shingler SL, Kosmas CE, Samanta K, et al. Health state utilities for chronic lymphocytic leukemia. Value Health 2014;17:A92
   Web of Science ®Google Scholar
• Woods B, Hawkins N, Dunlop W, et al. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis. Value Health 2012;15:759-70
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol Offic J Am Soc Clin Oncol 2009;27:4378-84
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015;385:1873-83
   PubMed Web of Science ®Google Scholar
• Holzner B, Kemmler G, Sperner-Unterweger B, et al. Quality of life measurement in oncology-a matter of the assessment instrument? Eur J Cancer. 2001;37:2349-56
   PubMed Web of Science ®Google Scholar